Lyme Disease Market to Witness Growth by 2032 | Major Players- Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics

DelveInsight's "Lyme Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Lyme Disease, historical and forecasted epidemiology as well as the Lyme Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Lyme Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Lyme Disease market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Lyme Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Lyme Disease market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/lyme-disease-ld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Lyme Disease: An Overview
Lyme disease is a tick-borne illness caused by the bacterium Borrelia burgdorferi. It is transmitted to humans through the bite of infected black-legged ticks, commonly known as deer ticks, which are found in wooded and grassy areas in many parts of the world, including the United States, Europe, and Asia.

The characteristic sign of Lyme disease is a distinctive skin rash known as erythema migrans, which typically appears within 3 to 30 days after a tick bite. This rash often starts as a small red bump that expands over time, resembling a bull's-eye, with a red outer ring surrounding a clear area and a red center. However, not everyone with Lyme disease develops this rash.

Symptoms of Lyme disease can vary and may resemble those of other conditions, making it sometimes challenging to diagnose. Early signs and symptoms may include fever, chills, fatigue, muscle and joint aches, headache, swollen lymph nodes, and the erythema migrans rash. If left untreated, Lyme disease can progress and lead to more severe symptoms affecting the joints, heart, and nervous system. These later-stage symptoms might include severe joint pain and swelling, neurological problems (such as facial paralysis or meningitis), and heart palpitations.

Diagnosing Lyme disease can be based on symptoms and history of tick exposure. Laboratory tests, such as blood tests to detect antibodies against the bacteria, may be performed to support the diagnosis.

Treatment for Lyme disease typically involves antibiotics. The choice of antibiotics and duration of treatment may vary depending on the stage and severity of the disease. Early treatment with antibiotics usually leads to a rapid and complete recovery. In some cases, however, symptoms may persist after treatment, leading to a condition called post-treatment Lyme disease syndrome (PTLDS), which may cause lingering fatigue, joint or muscle pain, and cognitive difficulties.

Preventing Lyme disease involves taking precautions when spending time in areas where ticks are prevalent. Some preventive measures include using insect repellents containing DEET, wearing long-sleeved clothing, performing tick checks after being outdoors, and promptly removing ticks with tweezers by grasping the tick's mouthparts close to the skin and pulling steadily without twisting.

Learn more about Lyme Disease, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/lyme-disease-ld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Lyme Disease Market

The Lyme Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Lyme Disease market trends by analyzing the impact of current Lyme Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Lyme Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Lyme Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Lyme Disease market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/lyme-disease-ld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Lyme Disease Epidemiology

The Lyme Disease epidemiology section provides insights into the historical and current Lyme Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Lyme Disease market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Lyme Disease Epidemiology at: https://www.delveinsight.com/report-store/lyme-disease-ld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Lyme Disease Emerging Drugs
VLA 15: Valneva
VLA15 is currently the only active vaccine program in clinical development against Lyme disease. VLA15 is a multivalent recombinant protein vaccine that targets six serotypes of Borrelia representing the most common pathogenic strains found in the United States and Europe. Valneva has completed recruitment and reported initial results for two Phase 2 clinical trials of VLA15 in over 800 healthy adults and in which Valneva observed high levels of antibodies against all six serotypes. Valneva announced a collaboration with Pfizer for late phase development and, if approved, commercialization of VLA15. As part of its collaboration with Pfizer, Valneva accelerated the pediatric development of VLA15 with an additional Phase 2 clinical trial initiated in March 2021. In July 2021, Pfizer and Valneva announced recruitment completion for VLA15-221 with a total of 625 participants, 5 to 65 years of age. The VLA15 program was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in July 2017
CT38: Cortene
CT38 is a potent, short-lived, peptide agonist selective for CRFR2. It is comprised entirely of naturally-occurring amino acids. It was tested in animals and in healthy humans in a Phase 1 clinical trial. These studies have defined the safety profile of CT38 in humans and show that CT38 only lasts a few hours in the body.

Lyme Disease Drugs Uptake

This section focuses on the uptake rate of the potential Lyme Disease drugs recently launched in the Lyme Disease market or expected to be launched in 2019-2032. The analysis covers the Lyme Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Lyme Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Lyme Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Lyme Disease Pipeline Development Activities

The Lyme Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Lyme Disease key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Lyme Disease pipeline development activities at: https://www.delveinsight.com/sample-request/lyme-disease-ld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Lyme Disease Therapeutics Assessment

Major key companies such as Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics, and others are working proactively in the Lyme Disease Therapeutics market to develop novel therapies which will drive the Lyme Disease treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/lyme-disease-ld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Lyme Disease Report Key Insights

1. Lyme Disease Patient Population
2. Lyme Disease Market Size and Trends
3. Key Cross Competition in the Lyme Disease Market
4. Lyme Disease Market Dynamics (Key Drivers and Barriers)
5. Lyme Disease Market Opportunities
6. Lyme Disease Therapeutic Approaches
7. Lyme Disease Pipeline Analysis
8. Lyme Disease Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Lyme Disease Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Lyme Disease Competitive Intelligence Analysis
4. Lyme Disease Market Overview at a Glance
5. Lyme Disease Disease Background and Overview
6. Lyme Disease Patient Journey
7. Lyme Disease Epidemiology and Patient Population
8. Lyme Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Lyme Disease Unmet Needs
10. Key Endpoints of Lyme Disease Treatment
11. Lyme Disease Marketed Products
12. Lyme Disease Emerging Therapies
13. Lyme Disease Seven Major Market Analysis
14. Attribute Analysis
15. Lyme Disease Market Outlook (7 major markets)
16. Lyme Disease Access and Reimbursement Overview
17. KOL Views on the Lyme Disease Market
18. Lyme Disease Market Drivers
19. Lyme Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Lyme Disease Market report here: https://www.delveinsight.com/sample-request/lyme-disease-ld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+91-9650213330
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.